Applied Molecular down on disappointing data from ulcerative colitis drug trial

Applied Molecular Transport.

22/12/2022 23:10

** Shares of drug developer Applied Molecular Transport Inc
 AMTI.O  fall ~5% to $0.98 after market
    ** Co reports data from mid-stage study of its experimental
drug, AMT-101, for treating patients with moderate-to-severe
ulcerative colitis (UC)
    ** Says clinical remission (CR) rate in UC patients treated
with AMT-101 as a monotherapy was 17.1%, compared with 20% with
placebo
    ** CR is based upon some scores used to determine healing of
the disease 
    ** Seeking to better understand "unexpectedly high placebo
rate of clinical remission" in the patient population - company 
    ** Adds that it plans to seek a partner to advance the
program into late-stage study 
    ** As of last close, stock was down ~93% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))